According to the cautious reflection of the actual situation of the business and the overall operation of the company, ST Tianmushan has decided to adjust the above business to recognize revenue according to the net amount method, and to make corrections to the relevant financial information in the company's first quarter report for 2024. This correction will reduce operating revenue by 10.5962 million yuan and cost of goods sold by 10.5962 million yuan in the financial statements of the company's first quarter report for 2024. It will not affect other accounting items in the financial statements of the company's first quarter report for 2024, and will not affect the financial statements data of the company's annual report for 2023, total assets, net assets and total profit.
*ST目药：对2024年第一季度报告会计差错进行更正
Hangzhou Tianmushan pharmaceutical enterprise: correction of accounting errors in the first quarter report of 2024.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.